Skip to main content
. 2019 May 28;13(5):e0007434. doi: 10.1371/journal.pntd.0007434

Table 2. The risk effect of comorbidities on fatal outcome in SFTS patients.

Outcome
Fatal Survival OR(95%CI) P value Adjusted Adjusted
OR(95%CI)# P value#
Without comorbidities 165 (12.5) 1152 (87.5) Reference Reference
One kind of comorbidity 123 (22.0) 436 (78.0) 1.970 (1.521–2.550) <0.001 1.631 (1.233–2.159) <0.001
    Hyperlipidemia 19 (13.2) 125 (86.8) 1.061 (0.638–1.766) 0.819 0.912 (0.520–1.601) 0.749
    Hypertension 24 (21.2) 89 (78.8) 1.883 (1.166–3.041) 0.010* 1.610 (0.956–2.710) 0.073
    Chronic viral hepatitis 26 (21.3) 96 (78.7) 1.891 (1.190–3.004) 0.007* 2.006 (1.215–3.311) 0.007*
    Diabetes 18 (27.7) 47 (72.3) 2.674 (1.516–4.715) 0.001* 2.462 (1.310–4.630) 0.005*
    COPD 16 (44.4) 20 (55.6) 5.585 (2.837–10.996) <0.001 2.715 (1.295–5.691) 0.008*
Two kinds of comorbidities 40 (22.4) 139 (77.6) 2.009 (1.363–2.961) <0.001 1.447 (0.955–2.194) 0.082
    Hypertension & Hyperlipidemia 7 (26.9) 19 (73.1) 2.572 (1.065–6.213) 0.036* 2.101 (0.822–5.370) 0.121
    Diabetes & Hyperlipidemia 7 (38.9) 11 (61.1) 4.443 (1.699–11.622) 0.002* 3.545 (1.184–10.620) 0.024*
    Chronic viral hepatitis & Hyperlipidemia 1 (5.3) 18 (94.7) 0.388 (0.051–2.925) 0.358 0.309 (0.040–2.409) 0.262
    Chronic viral hepatitis & Hypertension 3 (20.0) 12 (80.0) 1.745 (0.487–6.250) 0.392 1.010 (0.257–3.975) 0.989
    Diabetes & Hypertension 2 (12.5) 14 (87.5) 0.997 (0.225–4.428) 0.997 0.921 (0.198–4.287) 0.917
    Diabetes & Chronic viral hepatitis 5 (45.5) 6 (54.5) 5.818 (1.756–19.278) 0.004* 4.792 (1.345–17.077) 0.016*
Three or more kinds of comorbidities 12 (29.3) 29 (70.7) 2.889 (1.446–5.773) 0.003* 2.399 (1.128–5.106) 0.023*

#Adjusting for age, sex, time from disease onset to admission and treatment regimens (ribavirin, corticosteroid and immunoglobulin) by applying logistic regression model. The COPD was not listed in the two kinds of comorbidities due to the small sample size.

* P < 0.05.